These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29413684)

  • 21. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
    Ma J; Lyu H; Huang J; Liu B
    Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
    Desbois-Mouthon C
    Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Evolving Landscape of HER2 Targeting in Breast Cancer.
    Moasser MM; Krop IE
    JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
    Loree JM; Bailey AM; Johnson AM; Yu Y; Wu W; Bristow CA; Davis JS; Shaw KR; Broaddus R; Banks KC; Lanman RB; Meric-Bernstam F; Overman MJ; Kopetz S; Raghav K
    J Natl Cancer Inst; 2018 Dec; 110(12):1409-1417. PubMed ID: 29718453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
    Umelo I; Noeparast A; Chen G; Renard M; Geers C; Vansteenkiste J; Giron P; De Wever O; Teugels E; De Grève J
    Oncotarget; 2016 Jan; 7(3):3068-83. PubMed ID: 26689995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
    Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
    Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic ERBB3 mutations in human cancers.
    Jaiswal BS; Kljavin NM; Stawiski EW; Chan E; Parikh C; Durinck S; Chaudhuri S; Pujara K; Guillory J; Edgar KA; Janakiraman V; Scholz RP; Bowman KK; Lorenzo M; Li H; Wu J; Yuan W; Peters BA; Kan Z; Stinson J; Mak M; Modrusan Z; Eigenbrot C; Firestein R; Stern HM; Rajalingam K; Schaefer G; Merchant MA; Sliwkowski MX; de Sauvage FJ; Seshagiri S
    Cancer Cell; 2013 May; 23(5):603-17. PubMed ID: 23680147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
    Owonikoko TK; Khuri FR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
    Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y
    J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.